Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84825 | 0.84 | — | — | |
| SCHEMBL5147226 | 0.84 | KIF11 (0.64) | KIF11MAPTSMN1; SMN2ALDH1A1HPGD | |
| Fluoride SCHEMBL29031926 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL27865056 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL28137223 | 0.81 | CTSD (0.55) | KIF11MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL12240924 | 0.80 | RAD52 (0.60) | KIF11MAPTKDM4EALDH1A1POLB | |
| SCHEMBL21012394 | 0.79 | MAPT (0.61) | KIF11MAPTLMNASMN1; SMN2NOTUM | |
| SCHEMBL27893422 | 0.78 | KIF11 (0.44) | KIF11TSHRAAK1CYP3A4APP | |
| SCHEMBL135626 | 0.78 | MAPT (0.92) | KIF11MAPTLMNASMN1; SMN2NOTUM | |
| SCHEMBL10000032 | 0.78 | MAPT (0.92) | KIF11MAPTLMNASMN1; SMN2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4201404-A1 | ANTIVIRAL COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | Erasmus University Rotterdam Medical Center (NL) | 2023-06-28 | — | — | EP | disclosed |
| WO-2021135183-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS | 陕西莱特光电材料股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-10196376-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3312160-A1 | HEPATITIS B ANTIVIRAL AGENTS | Novira Therapeutics Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
| US-9751857-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9676747-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| CN-104744434-A | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORP | 2015-07-01 | — | — | CN | disclosed |
| US-9061008-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| CN-101277689-B | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA NV | 2011-01-12 | — | — | CN | disclosed |
| CN-101333219-B | Penem derivates with mercapto pyrrolidine formamide benzene alkyl heterocycle | SHANDONG XUANZHU PHARM TECH CO | 2010-10-13 | — | — | CN | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| CN-101528710-A | Aminomethyl-4-imidazoles | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | CN | disclosed |
| CN-101370792-A | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN INC (US) | 2009-02-18 | — | — | CN | disclosed |
| CN-101333219-A | Penem derivates with mercapto pyrrolidine formamide benzene alkyl heterocycle | SHANDONG XUANZHU MEDICAL SCI T (CN) | 2008-12-31 | — | — | CN | disclosed |
| CN-101277689-A | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-01 | — | — | CN | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| CN-100355751-C | 2-substd. 4-heteroaryl-pyrimidines and their use in treatment of proliferative disorders | CYCLACEL LTD (GB) | 2007-12-19 | — | — | CN | disclosed |
| CN-1420884-A | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative diseases | CYCLACEL LTD (GB) | 2003-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196376-B2 | Hepatitis B antiviral agents | HAVCR2, EIF2AK2, IRF3 | KIF11 3872/4885MAPT 4607/4885LMNA 3521/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | KIF11 3999/4885MAPT 3312/4885LMNA 3250/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | KIF11 2110/4885MAPT 21/4885LMNA 192/4885 |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | KIF11 3872/4885MAPT 4607/4885LMNA 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.